What single-stage and two-stage actually mean

The most practical question when considering knee cartilage repair is not which technique has the longest name — it is whether treatment requires one operation or two, weeks apart.

In a two-stage pathway, the surgeon performs an arthroscopic biopsy at the first operation to harvest a small sample of your own cartilage cells. Those cells are sent to a specialist laboratory, cultured for roughly four to six weeks, and then returned for a second procedure — usually an open or mini-arthrotomy — where the expanded cells are implanted into the damaged area. Two anaesthetics, two recovery periods, and a waiting interval between them are the defining features.

In a single-stage pathway, harvesting, any preparation, and implantation all happen within the same anaesthetic session. There is no laboratory phase and no second operation booked weeks later.

One misconception is worth correcting early: MACI (matrix-induced autologous chondrocyte implantation) is often described as a newer, simpler alternative to conventional ACI. It is not simpler in terms of staging. MACI's innovation was in how cells are delivered at the second operation — seeded onto a collagen membrane rather than injected under a periosteal patch — but the biopsy-then-culture-then-reimplant sequence remains unchanged. MACI is fundamentally two-stage.

This distinction matters for practical planning: cost, scheduling, time off work, and the willingness or ability to undergo two separate procedures all hinge on which pathway a technique belongs to.

How ACI, MACI, AMIC, and STACI each work

ACI (autologous chondrocyte implantation)

At the first operation, the surgeon arthroscopically removes a small sample of healthy cartilage — typically from a low-load area of the knee. The sample is sent to a specialist laboratory, where the cartilage cells (chondrocytes) are isolated and grown in culture for roughly six to eight weeks until sufficient numbers are available. At the second operation, those expanded cells are injected back into the prepared defect and sealed beneath a periosteal membrane harvested from the tibia. NICE-approved and in clinical use for more than 25 years, ACI remains the reference standard for two-stage cell-based knee cartilage repair.

MACI (matrix-induced autologous chondrocyte implantation)

MACI follows the same two-stage biopsy-then-culture pathway as conventional ACI. The difference lies at the second operation: instead of injecting cells under a periosteal flap, the laboratory seeds the cultured chondrocytes directly onto a porcine Type I/III collagen membrane. The surgeon then cuts and fixes this pre-seeded membrane to the defect, making implantation more straightforward than with earlier-generation ACI. The staging — two separate procedures separated by a laboratory phase — is unchanged. MACI is FDA-approved for full-thickness knee cartilage defects in adults.

AMIC (autologous matrix-induced chondrogenesis)

AMIC is completed in a single operative session with no laboratory phase. The surgeon first performs microfracture (or nanofracture), creating small perforations in the subchondral bone to release bone-marrow cells and a repair clot. A bi-layer collagen I/III scaffold is then immediately placed over the treated area and fixed in position — by suture or fibrin glue — to stabilise the clot and guide the marrow-derived cells towards cartilage-like tissue. AMIC is NICE-approved in the UK.

STACI (single-stage autologous chondrocyte implantation)

STACI aims to provide a chondrocyte-based repair without cell culture. During a single operation, the surgeon harvests a small cartilage fragment intraoperatively, minces it into chips using an enzymatic process, and combines the result with concentrated bone-marrow-derived mesenchymal stem cells (MSCs) or platelet-rich plasma drawn from the operative field. The mixture is implanted immediately onto a scaffold membrane. Described by Taylor and Lee (2019) as the next generation of ACI, STACI is an emerging technique; the evidence base is still accumulating and long-term comparative data against established two-stage methods remain limited.

Which patients suit each approach

Defect size is the most commonly cited starting point, but candidacy depends on several overlapping factors — and size alone rarely settles the question.

Defect size provides the clearest threshold. Below roughly 2 cm², simpler marrow-stimulation approaches may be sufficient. From approximately 2–4 cm² upwards, AMIC and cell-based options both become appropriate; the SUMMIT RCT established that MACI produces significantly better outcomes than microfracture for defects of 3 cm² or larger. ACI and MACI are typically indicated for defects up to around 10 cm², while published AMIC series cluster around 2–8 cm².

Stage-2 likelihood with MACI is less predictable than often assumed. A 2024 cohort study found that only 35% of patients who underwent a MACI Phase 1 biopsy actually required the implantation stage. Independent predictors of proceeding to Phase 2 were a larger defect (mean 5.2 cm² versus 3.3 cm² in non-progressors) and age 26 or older at biopsy — meaning the majority of biopsied patients may gain adequate benefit from the first operation and any concomitant work alone.

Prior marrow stimulation matters significantly. Previous microfracture can damage the subchondral bone plate in ways that raise the risk of ACI failure and may compromise future repair options.

Alignment and meniscal status can disqualify or substantially modify any cartilage repair plan. A varus knee that continues to overload the medial compartment, or one with significant meniscal deficiency, will typically require those issues addressed before or alongside any restorative procedure.

STACI suits patients who are keen to avoid a second anaesthetic, but the evidence base for the knee remains limited, and patients should be counselled explicitly on its emerging status.

Three questions are worth bringing to a consultant appointment: "How large is the defect on MRI, and does it reach the subchondral bone?" "Have I had previous microfracture or marrow-stimulation surgery?" and "Does my knee alignment or meniscal tissue need addressing first?" The answers to those three questions will shape the technique discussion more than defect size alone.

What the comparative evidence shows

Three randomised controlled trials and one matched-pair cohort form the backbone of what practitioners currently know — and they answer different questions.

The SUMMIT RCT is frequently cited as evidence for MACI's superiority, but its comparator was microfracture, not AMIC or ACI. For defects of 3 cm² or larger, MACI produced significantly better KOOS pain and function scores than microfracture at both 2 and 5 years — a meaningful finding about the limitations of marrow stimulation alone, not about where MACI stands relative to scaffold-based single-stage repair.

The most direct two-versus-one-stage comparison is the Fossum 2019 RCT (n=41), which pitted collagen-covered ACI against AMIC. At 2 years, no statistically significant difference emerged in KOOS, Lysholm score, or VAS pain; both groups improved substantially from baseline. A cautionary signal did appear: two AMIC patients (10%) progressed to total knee replacement within the follow-up period versus none in the ACI-C group. The trial was too small for this difference to reach significance, so the finding sits somewhere between a reassuring equivalence and an unresolved question about failure mode — worth noting, not dramatising.

AMIC's long-term durability is better characterised by a 10-year RCT against microfracture, which found both sutured and glued AMIC groups maintaining stable Cincinnati Knee and MOCART scores while the microfracture group deteriorated progressively after year 2 — a clear argument for scaffold augmentation over marrow stimulation alone.

The most contemporary cross-paradigm data come from a 2025 matched-pair study (n=48, MDPI) comparing MACI, AMIC, and minced cartilage implantation. At 2-year follow-up, no statistically significant difference was found between groups on VAS pain or KOOS; all three techniques produced significant improvement from baseline.

STACI does not yet appear in any of these comparative trials. The technique's place in the evidence hierarchy is genuinely different from the other three: case-series and biological rationale exist, but a head-to-head RCT against MACI or AMIC in the knee has not been conducted. That gap is significant — and it is the reason STACI features here as an emerging option rather than a ranked comparator.

Long-term durability and tissue quality

MRI data from a prospective 10-year follow-up of MACI grafts illustrate why tissue quality matters beyond the two-year mark. At 2 years, mean graft fill on MRI averaged 90%; by the decade mark that figure had fallen to 49%. Biopsy samples told a consistent story: 73% contained fibrocartilage rather than true hyaline cartilage, and 80% of grafts were mechanically softer than the surrounding native tissue.

The distinction is clinically relevant. Hyaline cartilage — the tissue lining a healthy joint surface — is stiffer, more resilient under load, and better suited to long-term weight-bearing; fibrocartilage is a repair tissue that may gradually soften under sustained mechanical stress. The important counterpoint is that imaging and biopsy findings do not map directly onto how patients function: many individuals in long-term MACI series report sustained clinical benefit even where MRI shows incomplete fill, suggesting that symptom outcomes and tissue quality tell partially independent stories.

AMIC's 10-year RCT established durable functional stability — stable Cincinnati Knee and MOCART scores at the decade mark while the microfracture group deteriorated progressively. However, that trial did not include systematic biopsy sampling, so the histological character of AMIC repair tissue at 10 years is less well documented than for MACI. That is an evidence gap on a specific endpoint, not a signal that the repair tissue is inferior.

For STACI, existing case series are too early and too small to report meaningful decade-level biopsy or imaging data. As those cohorts mature over the next five to ten years, histological findings will clarify whether the enzymatic digestion approach preserves enough viable chondrocyte character to support durable hyaline-like repair — a question that current data cannot yet answer.

Cost, recovery, and getting assessed in Lincolnshire

The financial gap between pathways is real and worth naming. UK private MACI or ACI costs £15,000–£25,000 or more, with the cell-culturing phase alone accounting for £10,000–£17,000; comparable procedures in the United States regularly exceed $60,000–$70,000. Single-stage procedures avoid both the laboratory cost and the second general anaesthetic, reducing total outlay — though they are not inexpensive, and the saving depends on technique and setting.

Rehabilitation timelines also differ in ways that matter for working-age patients. A Delphi consensus on MACI established 7–9 weeks of tibiofemoral weight-bearing restriction following surgery; AMIC protocols are generally less restrictive, which can affect how much time away from work or normal activity a patient needs to plan for.

Access is a separate obstacle. A 2025 nationwide study covering 19 UK centres recorded only 61 AMIC procedures and 176 ACI procedures over five years, while chondroplasty and microfracture continued to dominate practice. Guideline approval has not translated into widespread clinical availability.

Which pathway is realistic for a given patient depends on characterising the defect precisely — size, depth, subchondral bone status, and how load is distributed across the joint. At Lincolnshire Knee, pre-operative assessment uses onMRI™ cartilage segmentation alongside MAI Motion® biomechanical evaluation to map those characteristics before any technique discussion takes place.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without referral. Book an assessment at lincolnshireknee.co.uk.

1. [1] Rates and predictors of reimplantation of matrix-induced autologous chondrocyte implantation following first stage cartilage harvest: A cohort study. (2024). https://doi.org/10.1016/j.knee.2024.04.006 https://doi.org/10.1016/j.knee.2024.04.006
2. [2] Collagen-Covered Autologous Chondrocyte Implantation Versus Autologous Matrix-Induced Chondrogenesis: A Randomized Trial Comparing 2 Methods for Repair of Cartilage Defects of the Knee. (2019). https://doi.org/10.1177/2325967119868212 https://doi.org/10.1177/2325967119868212
3. [3] The management of cartilage defects of the knee and injection therapy – A collaborative and retrospective study. (2025). https://doi.org/10.1016/j.knee.2025.11.013 https://doi.org/10.1016/j.knee.2025.11.013
4. [4] [Two-Year Results of Modified AMIC Technique for Treatment of Cartilage Defects of the Knee]. (2020). https://doi.org/10.55095/achot2020/028 https://doi.org/10.55095/achot2020/028
5. [5] New and Emerging Techniques in Cartilage Repair: Matrix-Induced Autologous Chondrocyte Implantation (MACI). (2019). https://doi.org/10.1007/978-3-662-58704-1_11 https://doi.org/10.1007/978-3-662-58704-1_11
6. [6] A Prospective Outcome, MRI and Biopsy Study of MACI Cartilage Transplantation. (2017). https://doi.org/10.1177/2325967117S00186 https://doi.org/10.1177/2325967117S00186
7. [7] Single-Stage Arthroscopically Assisted 'Sandwich' Cancellous Bone and Minced Cartilage Implantation for Treatment of Osteochondral Lesions at the Knee Joint. (2025). https://doi.org/10.1016/j.eats.2025.103893 https://doi.org/10.1016/j.eats.2025.103893
8. [8] A randomized controlled trial demonstrating sustained benefit of autologous matrix-induced chondrogenesis (AMIC®) over microfracture: 10-year follow-up. (2024). https://doi.org/10.1007/s00590-024-03948-0 https://doi.org/10.1007/s00590-024-03948-0
9. [9] Consensus on Rehabilitation Guidelines among Orthopedic Surgeons in the United States following Use of Third-Generation Articular Cartilage Repair (MACI). (2020). https://doi.org/10.1177/1947603520968876 https://doi.org/10.1177/1947603520968876
10. [10] Autologous matrix-induced chondrogenesis – Wikipedia. https://en.wikipedia.org/?curid=29760859 https://en.wikipedia.org/?curid=29760859
11. [11] Focal Knee Cartilage Defect Treatment With Nanofracture and All-Arthroscopic Autologous Matrix-Induced Chondrogenesis Using Dry Arthroscopy. (2024). https://doi.org/10.1016/j.eats.2024.103272 https://doi.org/10.1016/j.eats.2024.103272